FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783131592> ?p ?o ?g. }

• W2783131592 endingPage "160" @default.
• W2783131592 startingPage "159" @default.
• W2783131592 abstract "Outcomes obtained with conventional chemotherapy treatments in patients with newly diagnosed acute lymphoblastic leukaemia worsen as age increases, with children displaying the most favourable end results and older patients the worst. Worse outcomes in older patients with acute lymphoblastic leukaemia are attributed to frequent presence of comorbidities, poor tolerance to intensive chemotherapy, and the different biological characteristics of acute lymphoblastic leukaemia at an older age, often displaying dissimilar patterns of sensitivity towards traditional chemotherapy agents. 1 Sallan SE Myths and lessons from the adult/pediatric interface in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2006; 2006: 128-132 Google Scholar , 2 O'Brien S Thomas DA Ravandi F et al. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer. 2008; 113: 2097-2101 Crossref PubMed Scopus (87) Google Scholar , 3 Li S Molony JT Chia V Katz AJ Patient characteristics and treatment patterns in elderly patients newly diagnosed with acute lymphoblastic leukemia (ALL) using 100% Medicare ALL data. Blood. 2016; 128: 3981 Crossref Google Scholar , 4 Geyer MB Hsu M Devlin SM Tallman MS Douer D Park JH Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis. Blood. 2017; 129: 1878-1881 Crossref PubMed Scopus (53) Google Scholar Additionally, prognosis further worsens as the disease shows resistance or relapses. New treatment options are therefore urgently needed in this area. Monoclonal antibodies represent, in the wider setting of immunotherapy, viable options to improve the results obtained in different subsets of patients with acute lymphoblastic leukaemia. Inotuzumab ozogamicin belongs to this category of agents and has shown encouraging activity and limited toxicity in adult and paediatric patients with relapsed or refractory acute lymphoblastic leukaemia. 5 Bhojwani D Sposto R Shah N et al. Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL). Proc Am Soc Clin Oncol. 2017; 35 (abstr).: 10512 Google Scholar , 6 Kantarjian H Ravandi F Short NJ et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016; 375: 740-753 Crossref PubMed Scopus (802) Google Scholar Inotuzumab ozogamicin is thus a promising agent that deserves to be explored in older patients as well. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 studyInotuzumab ozogamicin plus mini-hyper-CVD chemotherapy is a safe and active first-line therapy option in older patients with newly diagnosed acute lymphoblastic leukaemia and could represent a new therapy for this population. Randomised, phase 3 trials to evaluate the efficacy of this combination compared with the current standard of care in this setting, combination chemotherapy without inotuzumab ozogamicin, are warranted. Full-Text PDF" @default.
• W2783131592 created "2018-01-26" @default.
• W2783131592 creator A5057678079 @default.
• W2783131592 date "2018-02-01" @default.
• W2783131592 modified "2023-09-26" @default.
• W2783131592 title "Inotuzumab ozogamicin in older patients with acute lymphoblastic leukaemia: premises and promises" @default.
• W2783131592 cites W2070520252 @default.
• W2783131592 cites W2106742017 @default.
• W2783131592 cites W2346378690 @default.
• W2783131592 cites W2419639370 @default.
• W2783131592 cites W2582896768 @default.
• W2783131592 cites W2591881278 @default.
• W2783131592 cites W2783032930 @default.
• W2783131592 cites W2979686417 @default.
• W2783131592 cites W4234923904 @default.
• W2783131592 cites W2766375908 @default.
• W2783131592 doi "https://doi.org/10.1016/s1470-2045(18)30013-5" @default.
• W2783131592 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29352702" @default.
• W2783131592 hasPublicationYear "2018" @default.
• W2783131592 type Work @default.
• W2783131592 sameAs 2783131592 @default.
• W2783131592 citedByCount "1" @default.
• W2783131592 countsByYear W27831315922023 @default.
• W2783131592 crossrefType "journal-article" @default.
• W2783131592 hasAuthorship W2783131592A5057678079 @default.
• W2783131592 hasConcept C126322002 @default.
• W2783131592 hasConcept C143998085 @default.
• W2783131592 hasConcept C187212893 @default.
• W2783131592 hasConcept C203014093 @default.
• W2783131592 hasConcept C2776090121 @default.
• W2783131592 hasConcept C2776694085 @default.
• W2783131592 hasConcept C2776755627 @default.
• W2783131592 hasConcept C2777478502 @default.
• W2783131592 hasConcept C2778336483 @default.
• W2783131592 hasConcept C2778461978 @default.
• W2783131592 hasConcept C2779429289 @default.
• W2783131592 hasConcept C2781107101 @default.
• W2783131592 hasConcept C2909962599 @default.
• W2783131592 hasConcept C71924100 @default.
• W2783131592 hasConcept C8891405 @default.
• W2783131592 hasConceptScore W2783131592C126322002 @default.
• W2783131592 hasConceptScore W2783131592C143998085 @default.
• W2783131592 hasConceptScore W2783131592C187212893 @default.
• W2783131592 hasConceptScore W2783131592C203014093 @default.
• W2783131592 hasConceptScore W2783131592C2776090121 @default.
• W2783131592 hasConceptScore W2783131592C2776694085 @default.
• W2783131592 hasConceptScore W2783131592C2776755627 @default.
• W2783131592 hasConceptScore W2783131592C2777478502 @default.
• W2783131592 hasConceptScore W2783131592C2778336483 @default.
• W2783131592 hasConceptScore W2783131592C2778461978 @default.
• W2783131592 hasConceptScore W2783131592C2779429289 @default.
• W2783131592 hasConceptScore W2783131592C2781107101 @default.
• W2783131592 hasConceptScore W2783131592C2909962599 @default.
• W2783131592 hasConceptScore W2783131592C71924100 @default.
• W2783131592 hasConceptScore W2783131592C8891405 @default.
• W2783131592 hasIssue "2" @default.
• W2783131592 hasLocation W27831315921 @default.
• W2783131592 hasLocation W27831315922 @default.
• W2783131592 hasOpenAccess W2783131592 @default.
• W2783131592 hasPrimaryLocation W27831315921 @default.
• W2783131592 hasRelatedWork W1970500233 @default.
• W2783131592 hasRelatedWork W2016341751 @default.
• W2783131592 hasRelatedWork W2044836346 @default.
• W2783131592 hasRelatedWork W2066868518 @default.
• W2783131592 hasRelatedWork W2187646490 @default.
• W2783131592 hasRelatedWork W2342164759 @default.
• W2783131592 hasRelatedWork W2396471325 @default.
• W2783131592 hasRelatedWork W2402531250 @default.
• W2783131592 hasRelatedWork W2550808915 @default.
• W2783131592 hasRelatedWork W2917631767 @default.
• W2783131592 hasVolume "19" @default.
• W2783131592 isParatext "false" @default.
• W2783131592 isRetracted "false" @default.
• W2783131592 magId "2783131592" @default.
• W2783131592 workType "article" @default.